Showing 1 - 5 results of 5 for search 'Jacopo Vecchiet', query time: 0.01s Refine Results
  1. 1
    Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation

    Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation by Claudio Ucciferri, Antonio Auricchio, Jacopo Vecchiet, Katia Falasca

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Cardiac toxicity associated with HCV direct antiviral agents

    Cardiac toxicity associated with HCV direct antiviral agents by Claudio Ucciferri, Alessandro Occhionero, Jacopo Vecchiet, Katia Falasca

    Published 2018-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS

    PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS by Claudio Ucciferri, Barone Mirko, Jacopo Vecchiet, Katia Falasca

    Published 2020-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

    USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS by Paola Mancino, Katia Falasca, Claudio Ucciferri, Eligio Pizzigallo, Jacopo Vecchiet

    Published 2010-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

    USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS by Claudio Ucciferri, Katia Falasca, Paola Mancino, Eligio Pizzigallo, Jacopo Vecchiet

    Published 2010-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: